Powder: -20°C for 3 years | In solvent: -80°C for 1 year
ACT 178882 is a new Renin inhibitor (IC50: 1.4 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 10-14 weeks | $ 3,020.00 | |
50 mg | 10-14 weeks | $ 3,980.00 | |
100 mg | 10-14 weeks | $ 5,500.00 |
Description | ACT 178882 is a new Renin inhibitor (IC50: 1.4 nM). |
Targets&IC50 | Renin:1.4 nM |
In vitro | The median time to Cmax (tmax) for ACT 178882 is prolonged from 3.5 to 5.0 h by diltiazem whereas its apparent terminal half-life (t?) is unaffected by diltiazem, 22.9 and 24.2 h for treatments A and B, respectively. Using treatment A as reference, the geometric mean ratio (90% CI) is 1.62 (1.36 to 1.94) for Cmax and 2.02 (1.75 to 2.34) for AUC∞, indicating a significant interaction between ACT 178882 and diltiazem[2]. |
Molecular Weight | 647.03 |
Formula | C33H38Cl3N3O4 |
CAS No. | 1007392-69-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
ACT 178882 1007392-69-9 Endocrinology/Hormones RAAS ACT-178882 ACT178882 inhibitor inhibit